Biopsy News
-
Carcinotech and CELLINK Enter a Partnership to Develop and Commercialize Protocols for Cancer Models to Provide Improved Speed and Accuracy in the Drug Development Processes
Carcinotech and CELLINK are pleased to announce a collaborative partnership to develop and commercialize protocols for the biofabrication of 3D bioprinted tumor models based on cancer cell lines that improve accuracy and rapidly speed up drug development processes, driving down development costs and enabling an improved output. The protocols will be available for use on the BIO CELLX system ...
By CELLINK
-
CD Genomics’ RNA-Solutions Platform Now Supports Exosomal RNA Research
CD Genomics’ RNA-Solutions is a platform for revolutionary research in RNA, targeting coding and non-coding RNAs with different physiological functions. Based on rich RNA project experience and leading bioinformatics analytical capabilities, CD Genomics has launched a systematic solution for exosomal RNA research that assists in in-depth identification and functional analysis of exosomal ...
By CD Genomics
-
How Technology, Early Diagnoses Can Help Turn the Tide on Prostate Cancer Prognosis
Dr. Ali Tinazli's post at the Forbes magazine about "How Technology, Early Diagnoses Can Help Turn The Tide On Prostate Cancer Prognosis" There has never been more hope or promise in the global effort to eradicate cancer. Confidence in finding lifesaving cures is at an all-time high among medical researchers who work tirelessly for a solution. Astounding ...
-
Why Knowledge Is Power In The Treatment Of Obesity
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
-
Lynx Bio Makes Headway on New Diagnostic for Blood Cancer Drugs
In 2009, as a graduate student at the University of Wisconsin-Madison, Chorom Pak was part of a group of researchers working to understand how sensitive patients’ cells were to certain therapies for blood cancers, such as multiple myeloma. The group, which also included UW-Madison professors Shigeki Miyamoto and David Beebe, and postdoctoral fellow Edmond Young, would receive ...
-
Straight Outta Wisconsin, LynxBio Wins EvoNexus Best Demo Vote
A startup team from the University of Wisconsin that moved to San Diego in January to advance their technology for optimizing treatment regimens for cancer patients won the audience vote for best pitch at the EvoNexus Spring Demo Day last week. Lynx Biosciences founder and CEO Chorom Pak said her startup has developed microfluidic technology that uses live cancer cells to determine ...
-
BioMark Receives Funding, Support, Research and Development Project for Cancer Treatment Monitoring
BIOMARK RECEIVES FUNDING SUPPORTING RESEARCH AND DEVELOPMENT PROJECT FOR CANCER TREATMENT MONITORING Vancouver, British Columbia – (February 7th, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), an advanced stage liquid biopsy company with a focus on hard to detect and treat ...
-
Circulating Tumor Cell detection by Menarini Group’s CELLSEARCH System leading to genomic profiling of myeloma cells shows potential for non-invasive management of Multiple Myeloma patients at early stages of disease
Researchers at Dana-Farber Cancer Institute showed that enumeration of circulating tumor cells (CTCs) with Menarini Silicon Biosystems’ CELLSEARCH® System and the CELLSERCH® Circulating Multiple Myeloma Cell (CMMC) Test* can be used to monitor and manage patients with Multiple Myeloma (MM) even at asymptomatic precursor stages Menarini Silicon Biosystems, a pioneer of liquid biopsy ...
-
miR Scientific and Leonie Hill Capital Announce Collaboration to Introduce Breakthrough Urine Liquid Biopsy Prostate Cancer Test in Singapore
High demand seen for effective disease management platform for second most common cancer in Singaporean men NEW YORK and SINGAPORE, March 28, 2022 /PRNewswire/ -- miR Scientific, a New York-based healthcare company dedicated to transforming global cancer management, and Leonie Hill Capital, a Singapore-based organization focused on large-scale, sophisticated healthcare access and distribution, ...
-
Endosomal Signaling Of Delta Opioid Receptors Is An Endogenous Mechanism And Therapeutic Target For Relief From Inflammatory Pain
Whether G protein-coupled receptors signal from endosomes to control important pathophysiological processes and are therapeutic targets is uncertain. We report that opioids from the inflamed colon activate δ-opioid receptors (DOPr) in endosomes of nociceptors. Biopsy samples of inflamed colonic mucosa from patients and mice with colitis released opioids that activated DOPr on nociceptors to ...
-
Stilla and Promega Announce Co-Marketing Agreement to Offer Complete Digital PCR Workflow Solution
Stilla Technologies, the multiplex digital PCR company, and Promega Corporation today announced a co-marketing agreement that combines sample preparation with the latest Maxwell® systems and digital PCR on the six-color naica® system. With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, ...
-
Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new data supporting the clinical value of the Company’s skin cancer test portfolio is being shared in poster presentations at the 2023 Winter Clinical Dermatology Conference - Hawaii®, being held Jan. 13-18 in Kohala Coast, Hawaii. “At Castle, ...
-
4D Path Makes Continued Investments in Robust IT Infrastructure for Novel Precision Oncology Platform
4D Path applies universal physics, biology and mathematical principles to identify tumor-specific phenotypic and genotypic fingerprints. Its system runs on modern cloud components that enable dynamic scaling and batch processing, allowing 4D to optimize run times and deliver rapid results. Utilizing Microsoft Azure's cloud technology, 4D Path has built stable and secure ...
By 4D Path Inc.
-
4D Path Closes Latest Funding Round to Advance New Approach to Precise and Accelerated Cancer Diagnosis, Bringing Total to $6.4M
In 2019, 4D Path successfully closed a ~USD 4.4M funding round with the Seed Three Convertible Preferred Stock offering, bringing their total funds raised to $6.4M. The latest round will support legal and consulting costs as well as continued expansion of its research, team, infrastructure, data acquisition and business development. 4D Path’s patented precision oncology ...
By 4D Path Inc.
-
Biomark announces update from oongoing clinical trial using its lung cancer liquid biopsy test as it prepares for commercial launch
Vancouver, British Columbia – (January 11, 2023) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce several updates from ongoing clinical trial using the Company’s liquid biopsy test for ...
-
Biomark provides business update and second quarter financial results
Vancouver, British Columbia – (November 28, 2022) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to reports that it will amend the term of the non-broker warrants (the “Warrants”) issued in relation to ...
-
BIOMARK’s GLIOBLASTOMA Study Published in CANCERS Demonstrates Inhibiting SAT1 sensitized cancer cells towards radiation and chemotherapy
Vancouver, British Columbia – (October 27th, 2022) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers is pleased to announce today the publication of a preclinical study demonstrating therapeutic capabilities of its SAT1 cancer marker in glioblastoma (GB) ...
-
Berkshire and Surrey Pathology Services & ONCODNA announce formation of a national tissue collection centre that will facilitate private NGS testing across the UK
DR CHENG BOON, ONCOLOGIST IN THE PRIVATE SECTOR AND THE NHS AS WELL AS ACTING AS ONCODNA UK MEDIAL DIRECTOR COMMENTED: “In my view, this is an important first step in a collaboration that will make it much easier for public and privately practising oncologists to access biopsy tissue and request ONCODEEP* for the purpose of routine next generation sequencing. This unique public-private ...
By OncoDNA S.A.
-
Recognizing 10 years of philanthropic support for prostate cancer research
Two powerhouse researchers in prostate cancer will change the way we treat the disease, thanks to funding from legendary volunteer fundraisers, the Bird Dogs and the Alberta Cancer Foundation. Working with the Alberta Cancer Foundation and the University of Alberta, the Bird Dogs have enabled a new one-term, five-year chair position to further prostate cancer research — the Bird Dogs ...
-
Rarecells, Inc. to fund a clinical study at Columbia University of its ISET® -AML test for early detection of Acute Myeloid Leukemia (AML)
Rarecells, Inc., a healthcare company in the field of liquid biopsy, focused on the development and commercialization of non-invasive tests for early cancer detection, announced today that it has entered into an agreement with Columbia University to fund a clinical study evaluating its ISET -AML test for early detection of acute myeloid leukemia (AML) in patients with myelodysplastic syndrome ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you